Financial Performance - For the six months ended December 31, 2024, the company reported revenue of HKD 18,898,000, a slight increase from HKD 18,844,000 in the same period of 2023, representing a growth of 0.29%[6] - Gross profit for the same period was HKD 6,500,000, significantly up from HKD 3,121,000, indicating a year-over-year increase of 108.83%[6] - The company incurred a loss before tax of HKD 4,458,000, compared to a loss of HKD 2,239,000 in the previous year, reflecting an increase in losses of 99.57%[6] - The basic loss per share for the period was HKD 2.17, compared to HKD 1.57 in the prior year, indicating a deterioration in earnings per share[8] - The company's total comprehensive loss for the period was HKD 4,367,000, compared to a loss of HKD 3,315,000 in the previous year, representing an increase of 31.69%[8] - For the six months ended December 31, 2024, the company reported a loss attributable to shareholders of HKD 5,513,000, compared to a loss of HKD 2,876,000 for the same period in 2023, representing an increase in loss of approximately 92%[15] - The company recorded a pre-tax loss of HKD 5,513,000 for the six months ended December 31, 2024, compared to a pre-tax loss of HKD 2,876,000 for the same period in 2023, indicating a deterioration in financial performance[38] - The group reported a loss attributable to shareholders of HKD 5,500,000 in 2024, compared to a loss of HKD 2,900,000 in 2023[65] Assets and Liabilities - Total assets as of December 31, 2024, were HKD 39,004,000, compared to HKD 38,068,000 as of June 30, 2024, showing a slight increase of 2.45%[10] - Total assets as of December 31, 2024, amounted to HKD 44,682,000, an increase from HKD 44,490,000 as of June 30, 2024, reflecting a growth of 0.43%[25] - Current liabilities totaled HKD 63,193,000, a decrease from HKD 249,436,000, indicating a reduction of 74.69%[10] - Total liabilities increased to HKD 63,341,000 as of December 31, 2024, up from HKD 50,089,000 as of June 30, 2024, representing a rise of 26.4%[25] - The company’s total liabilities to total assets ratio increased to 1.42 as of December 31, 2024, compared to 1.12 as of June 30, 2024, indicating a higher financial leverage[25] - The debt-to-asset ratio improved to 12% as of December 31, 2024, down from 162% on June 30, 2024[75] Cash Flow and Financing - Cash and cash equivalents increased to HKD 3,347,000 at the end of the reporting period, compared to HKD 8,505,000 at the end of the previous year, reflecting a decrease of approximately 60%[18] - The company generated a net cash outflow from operating activities of HKD 781,000 for the six months ended December 31, 2024, compared to HKD 1,317,000 for the same period in 2023, showing a reduction in cash burn[18] - The company incurred financing costs of HKD 3,383,000 during the reporting period, contributing to the overall loss[22] - The company reported a significant increase in financing costs to HKD 3,383,000 from HKD 1,889,000, which is an increase of 79.00%[6] - The company issued convertible preferred shares amounting to HKD 148,015,000 as part of its financing activities during the period[15] - The company issued convertible bonds amounting to HKD 50,000,000 with a coupon rate of 7%[45] Inventory and Receivables - The company's inventory increased significantly to HKD 16,546,000 from HKD 3,537,000, marking a rise of 368.73%[10] - Trade receivables amounted to HKD 15,262,000 as of December 31, 2024, down from HKD 22,442,000 as of June 30, 2024, representing a decrease of 32%[41] - Other receivables and prepayments were HKD 6,257,000 as of December 31, 2024, compared to HKD 11,859,000 as of June 30, 2024, indicating a decline of 47%[41] - Total receivables, net of provisions for bad debts, stood at HKD 19,111,000 as of December 31, 2024, down from HKD 31,891,000 as of June 30, 2024, a decrease of 40%[41] Capital Structure and Shareholder Information - The company’s total equity attributable to shareholders decreased to HKD (13,919,000) as of December 31, 2024, from HKD (172,733,000) as of December 31, 2023, indicating a significant improvement in equity position[15] - As of December 31, 2024, the total issued and paid-up capital was HKD 155,936,000, up from HKD 57,404,000 as of July 1, 2024, an increase of 171%[51] - The company has established a stock option plan as of June 9, 2021, for incentivizing employees[94] - Directors and key executives hold a total of 1,600,000 ordinary shares each, representing 0.25% of the company’s equity[92] - Integrated Asset holds 321,694,520 shares, representing approximately 50.77% of the company's total shares[98] - Quantum Worldwide Investment Limited owns 150,000,000 shares, accounting for about 23.67% of the company's total shares[98] Corporate Governance and Compliance - The company has adhered to the GEM Listing Rules and corporate governance codes, with no significant deviations reported during the review period[124] - The audit committee, consisting of three independent non-executive directors, has reviewed the unaudited results for the six months ending December 31, 2024, ensuring compliance with applicable accounting standards[128] - The board of directors consists of executive directors Mr. Ho Kam Kin and Ms. Kwok Suk Yi; non-executive director Mr. Cheng Yan Kit; and independent non-executive directors Mr. Liu Fei, Mr. Xu Dong An, and Mr. Cheung Pik Lun[130] Future Outlook and Strategic Focus - The group is focusing on expanding its supply chain services and health products, aiming to enhance its revenue sources and market opportunities[73] - The company currently has no major future investment or capital asset plans, but will continue to monitor industry conditions[88] - The company has no knowledge of any significant matters affecting the group since the end of the reporting period[63]
国药科技股份(08156) - 2025 - 中期业绩